Hypothesis: Gender and encapsulating peritoneal sclerosis

Peritoneal Dialysis International

Volumn 29, Issue 5, 2009, Pages 489-491

  Guest, Steven ^a,b,c  

^a KAISER PERMANENTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

DIALYSATE; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENCAPSULATING PERITONEAL SCLEROSIS; FIBROBLAST; HORMONE ACTION; HUMAN; NONHUMAN; PATHOGENESIS; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; DIALYSIS; FEMALE; FIBROSIS; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; SEXUAL DEVELOPMENT;

ESTROGENS; FEMALE; HUMANS; MALE; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; SEX CHARACTERISTICS;

EID: 74349095494     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.1177/089686080902900502     Document Type: Review

References (26)

1. Nakamoto H. Encapsulating peritoneal sclerosis-a clinician's approach to diagnosis and medical treatment. Perit Dial Int 2005; 25(Suppl 4):S30-8.
2. Margetts PJ, Brimble KS. Peritoneal dialysis, membranes and beyond. Curr Opin Nephrol Hypertens 2006; 15:571-6.
3. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Heffernan J, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348:403-13.
4. Kawanishi H, Moriishi M. Encapsulating peritoneal sclerosis: prevention and treatment. Perit Dial Int 2007; 27(Suppl 2):S289-92.
5. Kawanishi H, Moriishi M, Tsuchiya S. Experience of 100 surgical cases of encapsulating peritoneal sclerosis: investigation of recurrent cases after surgery. Adv Perit Dial 2006; 22:60-4.
6. Nakamoto H, Kawaguchi Y, Suzuki H. Encapsulating peritoneal sclerosis in patients undergoing continuous ambulatory peritoneal dialysis in Japan. Adv Perit Dial 2002; 18:119-23.
7. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004; 44:729-37.
8. Chalasani R, Marella P. Sclerosing encapsulating peritonitis in a 47-year-old woman. Kidney Int 2006; 70:1673.
9. Sachdev A, Usatoff V, Thaow C. Sclerosing encapsulating peritonitis and methotrexate. Aust N Z J Obstet Gynaecol 2006; 46:58-9.
10. Thirunavukarasu T, Saxena R, Anijeet H, Pai P. Encapsulating peritoneal sclerosis presenting with recurrent ascites and tamoxifen: case reports and review of the literature. Ren Fail 2007; 29:775-6.
11. Lafrance J, Letourneau I, Ouimet D, Bonnardeaux A, Leblanc M, Mathieu N, et al. Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy. Am J Kidney Dis 2008; 51:e7-10.
12. Summers AM, Clancy MJ, Syed F, Harwood N, Brenchley P, Augustine T, et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int 2005; 68: 2381-8.
13. Campbell S, Clarke P, Hawley C, Wigan M, Kerlin P, Butler J, et al. Sclerosing peritonitis: identification of diagnostic, clinical, and radiological features. Am J Kidney Dis 1994; 24:819-25.
14. Rigby R, Hawley C. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998; 13:154-9.
15. Oules R, Challah S, Brunner FP. Case-control study to determine the cause of sclerosing peritoneal disease. Nephrol Dial Transplant 1988; 3:66-9.
16. Malet C, Gompel A, Yaneva H, Cren H, Fidji N, Mowszowicz I, et al. Estradiol and progesterone receptors in cultured normal human breast epithelial cells and fibroblasts: immunocytochemical studies. J Clin Endocrinol Metab 1991; 73:8-17.
17. Ashcroft GS, Dodsworth J, Van Boxtel E, Tarnuzzer R, Horan M, Schultz G, et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-1 levels. Nat Med 1997; 3:1209-15.
18. Wiczyk H, Grow D, Adams L, O'Shea D, Reece M. Pelvic adhesions contain sex steroid receptors and produce angiogenesis growth factors. Fertil Steril 1998; 69:511-16.
19. Grow DR, Coddington CC, Hsiu J, Mikich Y, Hodgen G. Role of hypoestrogenism or sex steroid antagonism in adhesion formation after myometrial surgery in primates. Fertil Steril 1996; 66:140-7.
20. Montanino-Oliva M, Metzger DA, Luciano AA. Use of medroxyprogesterone acetate in the prevention of postoperative adhesions. Fertil Steril 1996; 65:650-4.
21. Wright JA, Sharpe-Timms KL. Gonadotropin-releasing hormone agonist therapy reduces postoperative adhesion formation and reformation after adhesiolysis in rat models for adhesion formation and endometriosis. Fertil Steril 1995; 63:1094-100.
22. Guest S. Tamoxifen therapy for encapsulating peritoneal sclerosis: mechanism of action and update on clinical experiences. Perit Dial Int 2009; 29:252-5.
23. Ruffy M, Kunnavatana S, Koch R. Effects of tamoxifen on normal human dermal fibroblasts. Arch Facial Plast Surg 2006; 8:329-32.
24. Payne WG, Ko F, Anspaugh S, Wheeler CK, Wright TE, Robson MC. Down-regulating causes of fibrosis with tamoxifen: a possible cellular/molecular approach to treat rhinophyma. Ann Plast Surg 2006; 56:301-5.
25. Schneider G, Kirschner MA, Berkowitz R, Ertel NH. Increased estrogen production in obese men. J Clin Endocrinol Metab 1979; 48:633-8.
26. Loves S, Ruinemans-Koerts J, de Boer H. Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism. Eur J Endocrinol 2008; 158:741-7.